pyrimidine has been researched along with Hematologic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antony, T; Artin, E; Biller, SA; Choe, S; Chubukov, V; Coco, J; Dang, L; Erdmann, T; Fan, ZP; Fletcher, M; Gopinath, S; Hayes, S; Hurov, J; Jin, L; Lenz, G; Locuson, C; Mann, A; Marks, KM; McDonald, G; Murtie, J; Nagaraja, N; Narayanaswamy, R; Nellore, K; Padyana, AK; Panigrahi, SK; Rao, SS; Reddy, KS; Ronseaux, S; Steadman, M; Subramanya, H; Sui, Z; Truskowski, K; Ulanet, DB | 1 |
| Rew, DA; Wilson, GD | 1 |
1 review(s) available for pyrimidine and Hematologic Neoplasms
| Article | Year |
|---|---|
Cell production rates in human tissues and tumours and their significance. Part II: clinical data.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Central Nervous System Neoplasms; DNA; Esophageal Neoplasms; Female; Flow Cytometry; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Humans; Lasers; Lung Neoplasms; Melanoma; Neoplasms; Prognosis; Pyrimidines; S Phase; Time Factors | 2000 |
1 other study(ies) available for pyrimidine and Hematologic Neoplasms
| Article | Year |
|---|---|
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dihydroorotate Dehydrogenase; DNA Damage; Enzyme Inhibitors; Genomics; Hematologic Neoplasms; Humans; Neoplasm Staging; Oxidoreductases Acting on CH-CH Group Donors; Proteomics; Pyrimidines | 2020 |